Biomarkers and evolution in Alzheimer disease

Progress in Neurobiology

Volumn 95, Issue 4, 2011, Pages 510-513

  Rapoport, Stanley I ^a   Nelson, Peter T ^b  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer; Association; Biomarker; Brain; Cortex; Evolution; Metabolism; Neuroplasticity

Indexed keywords

BIOLOGICAL MARKER; GLUCOSE; RNA; TAU PROTEIN;

ALZHEIMER DISEASE; BRAIN REGION; CEREBROSPINAL FLUID LEVEL; DISEASE SEVERITY; GLUCOSE METABOLISM; HOMINID; HUMAN; NEOCORTEX; NERVE CELL PLASTICITY; NERVE FIBER; NEUROCHEMISTRY; NEUROFIBRILLARY TANGLE; NOTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SENILE PLAQUE; WHITE MATTER;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BIOLOGICAL EVOLUTION; BIOLOGICAL MARKERS; HUMANS; NEUROFIBRILLARY TANGLES; PLAQUE, AMYLOID;

EID: 82755193655     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2011.07.006     Document Type: Note

References (51)

1. Ashe K.H., Zahs K.R. Probing the biology of Alzheimer's disease in mice. Neuron 2010, 66:631-645.
2. Basselin M., Ramadan E., Igarashi M., Chang L., Chen M., Kraft A.D., Harry G.J., Rapoport S.I. Imaging upregulated brain arachidonic acid metabolism in HIV-1 transgenic rats. J. Cereb. Blood Flow Metab. 2011, 31:486-493.
3. Braak H., Braak E. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol. 1996, 92:197-201.
4. Buschert V., Bokde A.L., Hampel H. Cognitive intervention in Alzheimer disease. Nat. Rev. Neurol. 2010, 6:508-517.
5. Cogswell J.P., Ward J., Taylor I.A., Waters M., Shi Y., Cannon B., Kelnar K., Kemppainen J., Brown D., Chen C., Prinjha R.K., Richardson J.C., Saunders A.M., Roses A.D., Richards C.A. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J. Alzheimers Dis. 2008, 14:27-41.
6. de Leon M.J., Mosconi L., Li J., De Santi S., Yao Y., Tsui W.H., Pirraglia E., Rich K., Javier E., Brys M., Glodzik L., Switalski R., Saint Louis L.A., Pratico D. Longitudinal CSF isoprostane and MRI atrophy in the progression to AD. J. Neurol. 2007, 254:1666-1675.
7. DeCarli C.S., Atack J.R., Ball M.J., Kaye J.A., Grady C.L., Fewster P., Pettigrew K.D., Rapoport S.I., Schapiro M.B. Post-mortem regional neurofibrillary tangle densities but not senile plaque densities are related to regional cerebral metabolic rates for glucose during life in Alzheimer's disease patients. Neurodegeneration 1992, 1:113-121.
8. DeKosky S.T., Scheff S.W., Styren S.D. Structural correlates of cognition in dementia: quantification and assessment of synapse change. Neurodegeneration 1996, 5:417-421.
9. Di Patre P.L. Cytoskeletal alterations might account for the phylogenetic vulnerability of the human brain to Alzheimer's disease. Med. Hypotheses 1991, 34:165-170.
10. Esposito G., Giovacchini G., Liow J.S., Bhattacharjee A.K., Greenstein D., Schapiro M., Hallett M., Herscovitch P., Eckelman W.C., Carson R.E., Rapoport S.I. Imaging neuroinflammation in Alzheimer's disease with radiolabeled arachidonic acid and PET. J. Nucl. Med. 2008, 49:1414-1421.
11. Evans P.D., Anderson J.R., Vallender E.J., Choi S.S., Lahn B.T. Reconstructing the evolutionary history of microcephalin, a gene controlling human brain size. Hum. Mol. Genet. 2004, 13:1139-1145.
12. Evans P.D., Anderson J.R., Vallender E.J., Gilbert S.L., Malcom C.M., Dorus S., Lahn B.T. Adaptive evolution of ASPM, a major determinant of cerebral cortical size in humans. Hum. Mol. Genet. 2004, 13:489-494.
13. Fleisher A.S., Raman R., Siemers E.R., Becerra L., Clark C.M., Dean R.A., Farlow M.R., Galvin J.E., Peskind E.R., Quinn J.F., Sherzai A., Sowell B.B., Aisen P.S., Thal L.J. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch. Neurol. 2008, 65:1031-1038.
14. Furey M.L., Pietrini P., Haxby J.V., Alexander G.E., Lee H.C., VanMeter J., Grady C.L., Shetty U., Rapoport S.I., Schapiro M.B., Freo U. Cholinergic stimulation alters performance and task-specific regional cerebral blood flow during working memory. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:6512-6516.
15. Gilbert S.L., Dobyns W.B., Lahn B.T. Genetic links between brain development and brain evolution. Nat. Rev. Genet. 2005, 6:581-590.
16. Ginsberg L., Atack J.R., Rapoport S.I., Gershfeld N.L. Regional specificity of membrane instability in Alzheimer's disease brain. Brain Res. 1993, 615:355-357.
17. Ginsberg L., Gilbert D.L., Gershfeld N.L. Membrane bilayer assembly in neural tissue of rat and squid as a critical phenomenon: influence of temperature and membrane proteins. J. Membr. Biol. 1991, 119:65-73.
18. Grady C.L., Haxby J.V., Horwitz B., Sundaram M., Berg G., Schapiro M., Friedland R.P., Rapoport S.I. Longitudinal study of the early neuropsychological and cerebral metabolic changes in dementia of the Alzheimer type. J. Clin. Exp. Neuropsychol. 1988, 10:576-596.
19. Hampel H., Blennow K., Shaw L.M., Hoessler Y.C., Zetterberg H., Trojanowski J.Q. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp. Gerontol. 2010, 45:30-40.
20. Hatanpaa K., Brady D.R., Stoll J., Rapoport S.I., Chandrasekaran K. Neuronal activity and early neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 1996, 40:411-420.
21. Hatanpaa K., Chandrasekaran K., Brady D.R., Rapoport S.I. No association between Alzheimer plaques and decreased levels of cytochrome oxidase subunit mRNA, a marker of neuronal energy metabolism. Brain Res. Mol. Brain Res. 1998, 59:13-21.
22. Haxby J.V., Grady C.L., Koss E., Horwitz B., Heston L., Schapiro M., Friedland R.P., Rapoport S.I. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch. Neurol. 1990, 47:753-760.
23. Hebert S.S., De Strooper B. Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci. 2009, 32:199-206.
24. Ho L., Fivecoat H., Wang J., Pasinetti G.M. Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: experimental approaches and future clinical applications. Exp. Gerontol. 2010, 45:15-22.
25. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R.W., Bullock R., Love S., Neal J.W., Zotova E., Nicoll J.A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:216-223.
26. Horwitz B., Grady C.L., Schlageter N.L., Duara R., Rapoport S.I. Intercorrelations of regional cerebral glucose metabolic rates in Alzheimer's disease. Brain Res. 1987, 407:294-306.
27. Igarashi M., Ma K., Gao F., Kim H.W., Rapoport S.I., Rao J.S. Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer's disease prefrontal cortex. J. Alzheimers Dis. 2011, 24:507-517.
28. Kim H.W., Rapoport S.I., Rao J.S. Altered arachidonic acid cascade enzymes in postmortem brain from bipolar disorder patients. Mol. Psychiatry 2009, 16:419-428.
29. Kosik K.S. MicroRNAs tell an evo-devo story. Nat. Rev. Neurosci. 2009, 10:754-759.
30. Kosslyn S.M., Thompson W.L., Kim I.J., Alpert N.M. Topographical representations of mental images in primary visual cortex. Nature 1995, 378:496-498.
31. Kumar A., Schapiro M.B., Grady C., Haxby J.V., Wagner E., Salerno J.A., Friedland R.P., Rapoport S.I. High-resolution PET studies in Alzheimer's disease. Neuropsychopharmacology 1991, 4:35-46.
32. Luria A.R. The Working Brain. An Introduction to Neuropsychology 1973, Basic Bookd, New York.
33. Maunsell J.H.R. The brain's visual world: representation of visual targets in cerebral cortex. Science 1995, 270:764-769.
34. McGeer E.G., McGeer P.L. Inflammatory processes in Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:741-749.
35. Mentis M.J., Alexander G.E., Krasuski J., Pietrini P., Furey M.L., Schapiro M.B., Rapoport S.I. Increasing required neural response to expose abnormal brain function in mild versus moderate or severe Alzheimer's disease: PET study using parametric visual stimulation. Am. J. Psychiatry 1998, 155:785-794.
36. Morrison J.H., Hof P.R., Campbell M.J., DeLima A.D., Voigt T., Bouras C., Cox K., Young W.G. Cellular pathology in Alzheimer's disease: implications for corticocortical disconnection and differential vulnerability. Imaging, Cerebral Topography and Alzheimer's Disease, Research and Perspectives in Alzheimer's Disease 1990, 19-40. Fondation Ipsen, Springer-Verlag, Berlin. S.I. Rapoport, H. Petit, D. Leys, Y. Christen (Eds.).
37. Nelson P.T., Abner E.L., Schmitt F.A., Kryscio R.J., Jicha G.A., Smith C.D., Davis D.G., Poduska J.W., Patel E., Mendiondo M.S., Markesbery W.R. Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol. 2010, 20:66-79.
38. Nelson P.T., Keller J.N. RNA in brain disease: no longer just the messenger in the middle. J. Neuropathol. Exp. Neurol. 2007, 66:461-468.
39. Nelson P.T., Stefansson K., Gulcher J., Saper C.B. Molecular evolution of tau protein: implications for Alzheimer's disease. J. Neurochem. 1996, 67:1622-1632.
40. Rapoport S.I. Hypothesis: Alzheimer's disease is a phylogenetic disease. Med. Hypotheses 1989, 29:147-150.
41. Rapoport S.I. Integrated phylogeny of the primate brain, with special reference to humans and their diseases. Brain Res. Brain Res. Rev. 1990, 15:267-294.
42. Rapoport S.I. How did the human brain evolve? A proposal based on new evidence from in vivo brain imaging during attention and ideation. Brain Res. Bull. 1999, 50:149-165.
43. Reiman E.M., Chen K., Alexander G.E., Caselli R.J., Bandy D., Osborne D., Saunders A.M., Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:284-289.
44. Shaw P., Kabani N.J., Lerch J.P., Eckstrand K., Lenroot R., Gogtay N., Greenstein D., Clasen L., Evans A., Rapoport J.L., Giedd J.N., Wise S.P. Neurodevelopmental trajectories of the human cerebral cortex. J. Neurosci. 2008, 28:3586-3594.
45. Snowdon D.A., Greiner L.H., Markesbery W.R. Linguistic ability in early life and the neuropathology of Alzheimer's disease and cerebrovascular disease. Findings from the Nun Study. Ann. N. Y. Acad. Sci. 2000, 903:34-38.
46. Stephan H. Evolutionary trends in limbic structures. Neurosci. Biobehav. Rev. 1983, 7:367-374.
47. Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J. Int. Neuropsychol. Soc. 2002, 8:448-460.
48. Teipel S.J., Hampel H., Pietrini P., Alexander G.E., Horwitz B., Daley E., Moller H.J., Schapiro M.B., Rapoport S.I. Region-specific corpus callosum atrophy correlates with the regional pattern of cortical glucose metabolism in Alzheimer disease. Arch. Neurol. 1999, 56:467-473.
49. Wang W.X., Rajeev B.W., Stromberg A.J., Ren N., Tang G., Huang Q., Rigoutsos I., Nelson P.T. The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J. Neurosci. 2008, 28:1213-1223.
50. Yakovlev P.I., Lecours A.R. The myelogenetic cycles of regional maturation of the brain. Regional Development of the Brain in Early Life 1967, 3-70. F.A. Davis, Philadelphia. A. Minkowski (Ed.).
51. Zollikofer C.P., Ponce de Leon M.S. The evolution of hominin ontogenies. Semin. Cell Dev. Biol. 2010, 21:441-452.